Sanofi temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up.

France, Italy and Belgium acted to halt the use of hydroxychloroquine to treat patients suffering from COVID-19 amid questions about the safety of the generic anti-malaria drug.

Questions over the efficacy and safety of hydroxychloroquine continue to be raised following the World Health Organization’s decision to temporarily halt a study of the malaria drug as a potential treatment for COVID-19.

A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting patient safety.

The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.

The malaria drug hydroxychloroquine – which U.S. President Donald Trump says he has been taking – is tied to increased risk of death in COVID-19 patients, according to a study published in the medical journal Lancet.

BioSpace reviews some of the more interesting scientific studies recently published, including a Phase II clinical trial out of Hong Kong that found a three drug-antiviral cocktail significantly decreased median time to a negative SARS-CoV-2 test compared to controls.

A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

A look at which parts of the body the novel coronavirus infects and how SARS-CoV-2 is transmitted from person to person.

Toronto-based NoNO Inc. announced results from the pivotal Phase III ESCAPE-NA1 trial of intravenous nerinetide in patients with acute ischemic stroke who were chosen to undergo endovascular thrombectomy.